See more : Sabre Corporation (SABRP) Income Statement Analysis – Financial Results
Complete financial analysis of Rafarma Pharmaceuticals, Inc. (RAFA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rafarma Pharmaceuticals, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- CollPlant Biotechnologies Ltd. (CLGN) Income Statement Analysis – Financial Results
- Zhejiang Jingxing Paper Joint Stock Co., Ltd. (002067.SZ) Income Statement Analysis – Financial Results
- GSR II Meteora Acquisition Corp. (GSRM) Income Statement Analysis – Financial Results
- Murano Global Investments PLC Warrants (MRNOW) Income Statement Analysis – Financial Results
- IDEX Biometrics ASA (IDXAF) Income Statement Analysis – Financial Results
Rafarma Pharmaceuticals, Inc. (RAFA)
About Rafarma Pharmaceuticals, Inc.
Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wounds, inflammatory eye diseases, and immunological disorders. The company has a collaboration agreement with PlantEXT Ltd. to research and manufacture the first medical cannabis suppositories for patients suffering from inflammatory bowel disease. Rafarma Pharmaceuticals, Inc. was formerly known as Johnston Acquisition Corp. and changed its name to Rafarma Pharmaceuticals, Inc. in October 2012. The company is based in Sandy, Utah with a manufacturing and distribution facility in Russia. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.14M | 64.31M | 77.41M | 74.73M | 11.44M | 147.20K | 125.10K | 0.00 | 0.00 |
| Cost of Revenue | 9.54M | 41.50M | 50.14M | 41.65M | 8.09M | 143.59K | 195.94K | 0.00 | 0.00 |
| Gross Profit | 600.00K | 22.81M | 27.27M | 33.08M | 3.36M | 3.61K | -70.84K | 0.00 | 0.00 |
| Gross Profit Ratio | 5.92% | 35.47% | 35.23% | 44.27% | 29.32% | 2.45% | -56.63% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 150.00K | 5.42M | 5.36M | 8.10M | 0.00 | 9.20K | 26.23K | 1.00K | 0.00 |
| Other Expenses | 137.00K | -10.25M | -7.19M | -5.90M | -262.09K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 287.00K | 15.66M | 12.55M | 14.00M | 262.09K | 9.20K | 26.23K | 1.00K | 0.00 |
| Cost & Expenses | 9.82M | 57.16M | 62.69M | 55.65M | 8.35M | 152.79K | 222.17K | 1.00K | 0.00 |
| Interest Income | 0.00 | 599.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 7.00K | 39.38K | 595.00 | 0.00 | 13.85K | 0.00 |
| Depreciation & Amortization | 167.90K | 228.49K | 236.56K | 206.30K | 466.00K | 161.14K | 52.52K | 0.00 | 0.00 |
| EBITDA | 313.00K | 6.23M | 14.73M | 19.08M | 3.56M | -5.58K | -97.07K | -1.00K | 0.00 |
| EBITDA Ratio | 3.09% | 11.12% | 19.02% | 25.54% | 31.11% | -3.79% | -77.60% | 0.00% | 0.00% |
| Operating Income | 313.00K | 7.15M | 14.73M | 19.08M | 3.09M | -5.58K | -97.07K | -1.00K | 0.00 |
| Operating Income Ratio | 3.09% | 11.12% | 19.02% | 25.53% | 27.03% | -3.79% | -77.60% | 0.00% | 0.00% |
| Total Other Income/Expenses | 47.00K | -925.00K | -138.00K | -519.00K | -39.38K | -599.00 | 0.00 | -13.85K | 0.00 |
| Income Before Tax | 360.00K | 6.23M | 14.59M | 18.56M | 3.05M | -6.18K | -97.07K | -14.85K | 0.00 |
| Income Before Tax Ratio | 3.55% | 9.68% | 18.84% | 24.84% | 26.69% | -4.20% | -77.59% | 0.00% | 0.00% |
| Income Tax Expense | 87.00K | 1.26M | 3.01M | 3.72M | 0.00 | 4.00 | -52.52K | 0.00 | 0.00 |
| Net Income | 273.00K | 4.96M | 11.57M | 14.85M | 3.05M | -6.18K | -97.07K | -14.85K | 0.00 |
| Net Income Ratio | 2.69% | 7.71% | 14.95% | 19.87% | 26.69% | -4.20% | -77.59% | 0.00% | 0.00% |
| EPS | 0.00 | 0.06 | 0.13 | 0.17 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.06 | 0.13 | 0.17 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 87.77M | 87.77M | 87.77M | 87.77M | 93.17M | 83.87M | 83.87M | 82.87M | 77.67M |
| Weighted Avg Shares Out (Dil) | 87.77M | 87.77M | 87.77M | 87.77M | 93.17M | 83.87M | 83.87M | 82.87M | 77.67M |
Rafarma pharmaceutical updates: registration of Rafarma microspheres in South Korea
Rafarma pharmaceutical updates: creation of a joint research and production enterprise in Busan (South Korea) between Rafarma and the Korean pharmaceutical company Woods Medical Care
Rafarma pharmaceutical updates: agreements with Shri Lanka pharmaceutical company Kelun Lifesciences (Pvt) Ltd and El Salvador University
Rafarma Pharmaceutical news update
Rafarma Enters Negotiations With Leading Global Producer of Precious Metals to Localize Production of Platinum-Based Cancer Drugs
Letter to Shareholders from the Chairman of the Board Ilya Shpurov
Rafarma Signs Trilateral Investment Agreement Officially Launching Tashkent Pharmaceutical Plant Build
Rafarma's Global Pharmaceutical Strategy At A Glance
Rafarma To Expand Proton Therapy Centers
Rafarma and Haifa Technopark Enter Talks for Joint Venture
Source: https://incomestatements.info
Category: Stock Reports